top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Jeffrey S. Bornstein net worth and biography

Jeffrey Bornstein Biography and Net Worth

Director of AlloVir

Mr. Bornstein serves as a managing partner of Whipstick Ventures and Generation Capital, and was the Chief Financial Officer and Vice Chairman of General Electric until October 2017. Previously, Mr. Bornstein served as a Senior Vice President and Chief Financial Officer of GE Capital. He is a trustee of Northeastern University, and a member of the Board of Directors of buildOn, Inc. Mr. Bornstein obtained his BS degree from Northeastern University.

What is Jeffrey S. Bornstein's net worth?: The estimated net worth of Jeffrey S. Bornstein is at least $30,670.31 as of April 26th, 2022. Mr. Bornstein owns 40,197 shares of AlloVir stock worth more than $30,670 as of April 23rd. This net worth estimate does not reflect any other assets that Mr. Bornstein may own. Learn More about Jeffrey S. Bornstein's net worth.
How do I contact Jeffrey S. Bornstein?: The corporate mailing address for Mr. Bornstein and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on Jeffrey S. Bornstein's contact information.
Has Jeffrey S. Bornstein been buying or selling shares of AlloVir?: Jeffrey S. Bornstein has not been actively trading shares of AlloVir in the last ninety days. Most recently, on Tuesday, April 26th, Jeffrey S. Bornstein bought 5,000 shares of AlloVir stock. The stock was acquired at an average cost of $4.64 per share, with a total value of $23,200.00. Following the completion of the transaction, the director now directly owns 40,197 shares of the company's stock, valued at $186,514.08. Learn More on Jeffrey S. Bornstein's trading history.
Who are AlloVir's active insiders?: AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.
Are insiders buying or selling shares of AlloVir?: In the last year, AlloVir insiders bought shares 1 times. They purchased a total of 2,930,870 shares worth more than $10,990,762.50. In the last year, insiders at the sold shares 37 times. They sold a total of 180,585 shares worth more than $275,701.48. The most recent insider tranaction occured on April, 2nd when General Counsel Edward Miller sold 368 shares worth more than $283.36. Insiders at AlloVir own 40.0% of the company. Learn More about insider trades at AlloVir.
Information on this page was last updated on 4/2/2024.

Jeffrey S. Bornstein Insider Trading History at AlloVir

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/26/2022	Buy	5,000	$4.64	$23,200.00	40,197
2/10/2022	Buy	5,000	$8.87	$44,350.00

Jeffrey S. Bornstein Buying and Selling Activity at AlloVir

AlloVir Company Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Today's Range

Now: $0.76

$0.75

$0.76

50 Day Range

MA: $0.74

$0.67

$0.80

2 Week Range

Now: $0.76

$0.62

$6.12

Volume

173,549 shs

Average Volume

1,199,540 shs

Market Capitalization

$87.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86